XPH vs. BMY
XPH (SPDR S&P Pharmaceuticals ETF) is Health & Biotech Equities fund tracking the S&P Pharmaceuticals Select Industry Index, while BMY (Bristol-Myers Squibb Company) is a stock. Over the past 10 years, XPH returned 5.45%/yr vs 1.07%/yr for BMY. A 0.53 correlation means they provide meaningful diversification when combined.
Performance
XPH vs. BMY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, XPH achieves a 13.09% return, which is significantly higher than BMY's 5.24% return. Over the past 10 years, XPH has outperformed BMY with an annualized return of 5.45%, while BMY has yielded a comparatively lower 1.07% annualized return.
XPH
- 1D
- 1.77%
- 1M
- 9.48%
- YTD
- 13.09%
- 6M
- 12.03%
- 1Y
- 55.30%
- 3Y*
- 16.62%
- 5Y*
- 5.15%
- 10Y*
- 5.45%
BMY
- 1D
- 1.52%
- 1M
- -6.61%
- YTD
- 5.24%
- 6M
- 4.58%
- 1Y
- 24.26%
- 3Y*
- -0.64%
- 5Y*
- 0.61%
- 10Y*
- 1.07%
XPH vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
XPH SPDR S&P Pharmaceuticals ETF | 13.09% | 31.60% | 4.94% | 2.97% | -9.83% | -10.54% | 14.68% | 25.61% | -15.32% | 12.05% |
BMY Bristol-Myers Squibb Company | 5.24% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
Correlation
The correlation between XPH and BMY is 0.47, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.47 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.44 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.44 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.47 |
Correlation (All Time) Calculated using the full available price history since Jun 22, 2006 | 0.53 |
The correlation between XPH and BMY has been stable across timeframes, ranging from 0.44 to 0.53 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
XPH vs. BMY — Risk / Return Rank
XPH
BMY
XPH vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Pharmaceuticals ETF (XPH) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| XPH | BMY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.65 | ||
| Sortino ratioReturn per unit of downside risk | +1.95 | ||
| Omega ratioGain probability vs. loss probability | 1.41 | 1.17 | +0.24 |
| Calmar ratioReturn relative to maximum drawdown | 4.64 | 1.95 | +2.70 |
| Martin ratioReturn relative to average drawdown | 16.63 | 4.41 | +12.22 |
Loading charts...
Drawdowns
XPH vs. BMY - Drawdown Comparison
The maximum XPH drawdown since its inception was -48.03%, smaller than the maximum BMY drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for XPH and BMY.
Loading charts...
Drawdown Indicators
| XPH | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -48.03% | -72.03% | +24.00% |
Max Drawdown (1Y)Largest decline over 1 year | -11.97% | -12.53% | +0.56% |
Max Drawdown (3Y)Largest decline over 3 years | -23.57% | -36.02% | +12.45% |
Max Drawdown (5Y)Largest decline over 5 years | -31.63% | -47.67% | +16.04% |
Max Drawdown (10Y)Largest decline over 10 years | -35.97% | -47.67% | +11.70% |
Current DrawdownCurrent decline from peak | 0.00% | -20.09% | +20.09% |
Average DrawdownAverage peak-to-trough decline | -17.21% | -22.38% | +5.17% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.33% | 5.51% | -2.18% |
Volatility
XPH vs. BMY - Volatility Comparison
The current volatility for SPDR S&P Pharmaceuticals ETF (XPH) is 6.27%, while Bristol-Myers Squibb Company (BMY) has a volatility of 8.49%. This indicates that XPH experiences smaller price fluctuations and is considered to be less risky than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| XPH | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.27% | 8.49% | -2.22% |
Volatility (6M)Calculated over the trailing 6-month period | 16.67% | 18.04% | -1.37% |
Volatility (1Y)Calculated over the trailing 1-year period | 21.77% | 26.96% | -5.19% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.92% | 24.08% | -3.16% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.09% | 25.30% | -3.21% |
Dividends
XPH vs. BMY - Dividend Comparison
XPH's dividend yield for the trailing twelve months is around 0.53%, less than BMY's 4.50% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 4.50% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
XPH SPDR S&P Pharmaceuticals ETF | 0.53% | 0.83% | 1.58% | 1.28% | 1.64% | 0.95% | 0.47% | 0.64% | 0.65% | 0.67% | 0.63% | 7.15% |
Frequently Asked Questions
XPH and BMY have a correlation of 0.47, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BMY has higher volatility (8.49%) compared to XPH (6.27%). In terms of maximum drawdown, XPH dropped -48.03% vs BMY's -72.03%.
XPH currently has the higher Sharpe Ratio (2.55 vs 0.90), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for XPH and BMY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer